Growth Hormone Research Society Workshop
Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome

Cheri L Deal,1 Michèle Tony2, Charlotte Höybye3, David B. Allen4, Maïthé Tauber5, Jens Sandahl Christiansen6, and the 2011 GH in PWS Clinical Care Guidelines Workshop Participants.a

Research Center and Department of Pediatrics1, CHU-Sainte-Justine and Department of Public Health2, Université de Montréal, Montréal, Canada; Department of Endocrinology, Metabolism and Diabetes3, Karolinska University Hospital, Stockholm, Sweden; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health4, Madison, WI; Department of Endocrinology, Hôpital des Enfants and Université Paul Sabatier5, Toulouse, France; Department of Endocrinology and Diabetes6, Aarhus University Hospital, Aarhus, Denmark

Context: rhGH therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the US in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge which includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events.

Objective: To formulate recommendations for the use of rhGH in children and adult patients with PWS.

Evidence: A systematic review of the clinical evidence in the pediatric population, including randomized controlled trials (RCTs), comparative observational studies and long term studies (>3.5 years). Adult studies included RCTs of rhGH treatment for ≥6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials and pharmaceutical registries.

Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (www.evidem.org/praderwilli).

Conclusions: Following a multi-disciplinary evaluation preferably by experts, rhGH treatment should be considered for patients with genetically-verified PWS in conjunction with dietary, environmental and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.

Prader-Willi syndrome (PWS) is a rare genetic disorder (OMIM: #176270) characterized by hypotonia, poor feeding in infancy, hyperphagia with evolving obesity, hypogonadism, decreased adult height, and cognitive and behavioral disabilities (1, 2).

The birth incidence of PWS is difficult to ascertain, but data from several studies suggest that it is at least 1 in...
25,000 live births. PWS is genetically heterogeneous; in
approximately 65%–70% of patients PWS results from a
deletion of the paternally inherited chromosomal 15q11.2–q13 region (DEL15), 25%–30% from maternal
uniparental disomy for chromosome 15 (UPD15), while
~1% have imprinting defects (ID) or translocations in-
volving chromosome 15 (2, 3).

The therapeutic rationale for use of recombinant hu-
man growth hormone (hGH) (rhGH) is derived from our
understanding of the comorbidities seen in PWS, which
resemble those seen in association with growth hormone
(GH) deficiency (GHD) (e.g., reduced muscle strength,
altered body composition, low energy expenditure and
reduced growth even in the presence of obesity). Although
the etiology of impaired GH secretion in PWS remains
controversial due to the common occurrence of obesity,
the serum levels of IGF-I are reduced in most children
(4–6) and adults (7) with PWS, and excess body fat is seen
in even nonobese affected children (8, 9). Reduced GH
responses to a variety of GH secretagogues, as well as
decreased 24-h spontaneous GH release, have been doc-
umented in 58%–100% of affected children (10). Informa-
tion regarding GH secretory pattern in adult patients
with PWS is more limited, and suggests more variability,
with many potential explanations (7, 11–13).

Short-term rhGH treatment of children with PWS was
first reported in 1987 (14). It has been used by many mem-
ers of the international medical community and advocate-
ced by parental support groups since its FDA approval
in 2000 for use in children with PWS, based on short term
growth data and subsequently for its effects on body com-
position. However, the use of rhGH therapy for this con-
dition represents a unique therapeutic challenge which in-
cludes treating individuals with cognitive disability, varied
therapeutic goals that are not focused exclusively on in-
creased height, (15), and concerns about potential life-
threatening adverse events (16).

Prior expert consensus documents discuss the general
care of patients with PWS, including some discussion of
rhGH therapy in children and adults with PWS, (17, 18)
although many questions remained, particularly the ef-
fects on functional outcome and on long-term body com-
oposition changes. Recent pertinent publications have since
appeared, (19–29) and the Growth Hormone Research
Society therefore held a Consensus Workshop in order to
systematically review the literature and grade the available
evidence (30, 31) and provide concise recommendations
for the use of rhGH in this context with adherence to The
Principle of Respect for Persons (32) as the guiding ethical
principle for rhGH use in PWS (i.e., provision of care and
protection of patients who do not have autonomy).

The objective of the workshop was to evaluate the ef-
effects of rhGH therapy in pediatric and adult patients with
PWS and provide evidence-based guidelines for its use,
summarized herein.

Workshop Methodology

Forty-three experts (pediatric and adult endocrinolo-
gists, clinical and basic geneticists, epidemiologists, a nu-
trition specialist, an orthopedic surgeon, a psychiatrist,
health technology assessment (HTA) specialists, a bioeth-
cist, health economist, and a patient advocate) partici-
ated by invitation from the scientific committee (see au-
thor list). Clinical representatives from 5 manufacturers
of rhGH also submitted their PWS-specific safety data.

Prior to the workshop, an extensive literature review
based on a multicriteria methodology (30, 31) was per-
formed to identify relevant available data concerning
rhGH treatment for patients with PWS. For clinical evi-
dence in the pediatric population, RCTs, (20–26, 33–41)
comparative observational studies (42–48) and long term
studies (>3.5 y) (5, 49–58) were included. Adult studies
included RCTs of rhGH treatment for [mteq] 6 mo (7, 29,
59, 60) and uncontrolled trials, (61–64) since data were
more limited. Safety data from pharmaceutical registries
(phase 4 trials) (1) and sponsored clinical trials (phase 3)
were reviewed. Data on disease, therapeutic context, and
economic, ethical and societal aspects were also included
to reflect a broad international context. Details on ap-
proach, evidence tables and data summaries are available
in Supp Table 1a,b and on the workshop website (65).

Level of evidence was evaluated using the scoring pro-
cedure based on the Oxford Centre for Evidence-based
Medicine (CEBM) Level of Evidence scale (66). (Supp Ta-
ble 1c) Strength of evidence was graded independently by
two of the authors (CD and MT) using the EVIDEM Qual-
ity Assessment (QA) instrument, (30, 67) and a quality
grade on a 4-point scale (low to excellent) was then as-
signed to each publication. In the rare cases of disagree-
ment, the study was re-examined jointly.

Synthesized information by criteria was then provided
to workshop participants prior to the workshop discus-
sions for i) validation of content, and ii) to provide back-
ground information to answer relevant questions concern-
ing GH and PWS (Supp Table 2).

Based on 2 d of structured talks and breakout sessions,
participants formulated and categorized levels of recom-
endations using the following system:

Abbreviations:
A: Evidence or general agreement that a given procedure of treatment is beneficial, useful and effective

B: Weight of evidence is in favor of usefulness or efficacy

C: Usefulness or efficacy is less well established by evidence or opinion

D: Evidence or general agreement that the procedure or treatment is not useful or effective and in some cases may be harmful.

To each recommendation, a CEBM level of evidence score was assigned to reflect the origins of the data which lead to the recommendation.

Overview of Evidence Quality

Multiple pediatric RCTs with rhGH have reported statistically significant effects in patients with PWS on growth, body composition, resting energy expenditure, motor development (infants and children), muscle strength, exercise tolerance, bone health and lipid profiles. (20–26, 33–41, 50) Overall, these trials have been performed in small populations and durations were short compared to the length of rhGH treatment in the real life setting; quality grade ranged from low (10 publications) to high (1 publication). There is only one placebo-controlled study (35) and one controlled dose-response study (34) in the pediatric population, although the adult trials include placebo-controlled groups (7, 29, 59, 60). Most patients had genetically-confirmed diagnoses. Methodological issues were noted in several studies including incomplete reporting of patient numbers, lack of discussion of randomization methods, rare inclusion of intent-to-treat analyses, limited statistical details (P-values only), and minimal information about important confounders (e.g., socio-economic status, degree of adherence to diet, exercise plan). Only 2 studies reported individual patient responses (26, 33).

It is difficult to criticize the validity of these studies based on flawed methodologies, since the effects are consistent at least in the short term (1 y data), as demonstrated by recent meta-analyses in children and adults (19, 28). There are data regarding clear benefits to rhGH treatment in infants, childhood, adolescence, transition to adulthood, and in young adulthood, but there are less long-term data available after the fourth decade.

Summary of Recommendations

The workshop participants established 15 recommendations dealing with rhGH use in PWS, as shown in Table 1.

Considerations specific to each recommendation are discussed in a companion review (68) and are briefly summarized here.

Baseline evaluation of the GH-IGF Axis before rhGH treatment

Previous expert opinions (17) have suggested that GH testing is not necessary in children with PWS, although some countries require it in order for treatment reimbursement. It was agreed that over 50% of infants and children with PWS are, or will become GH deficient by standard testing protocols (4, 10, 26, 38, 50, 69–73). No consensus was reached concerning the frequency of testing in cases where GH sufficiency is initially documented. Determining the presence of GHD after attainment of adult height may be beneficial, however, since reports from dynamic testing in adults suggest that GHD is not universal, and many countries require testing prior to treatment of adults with GHD (28). It is not known if GH secretory status predicts metabolic response to rhGH treatment. Furthermore, within a research context, and in order to increase our understanding of genotype-phenotype relationships, GH testing may be desirable. Since serum IGF-I is a useful biomarker for monitoring compliance with treatment as well as sensitivity to GH, all participants agreed that baseline IGF-I levels should be determined.

Additional considerations prior to starting rhGH treatment

All participants agreed that evaluation of patients prior to beginning treatment should ideally include a complete assessment coordinated by a multidisciplinary team with expertise in PWS, and summarized in Table 2. This stems from the importance of diagnosing and treating comorbidities that may impact on GH safety as well as on GH response.

Product labeling information for all of the rhGH preparations commercially available (regardless of approved diagnosis) lists several contraindications to rhGH use, including acute critical illness, severe obesity or severe respiratory impairment, active malignancy, active proliferative or severe nonproliferative diabetic retinopathy, and hypersensitivity to the product. Workshop participants acknowledged these exclusion criteria and felt that active psychosis should also be included. Psychiatric illness is now increasingly recognized in patients with PWS (74).

Careful attention should be given to the clinical criteria used to define severe pediatric obesity, since there are no clear definitions as in adults (BMI > 40 kg/m^2). Workshop participants felt it prudent to consider obesity in the pediatric population with PWS as “severe” if a child with a BMI over the 95th percentile manifests complications of obesity such as sleep apnea, nonalcoholic fatty liver disease, or abnormalities of carbohydrate metabolism. Since treatment with rhGH decreases insulin sensitivity, uncontrolled diabetes mellitus, regardless of the presence or ab-
Table 1. Summary of Clinical Care Guidelines for rhGH Therapy in PWS

I. After genetic confirmation of the diagnosis of PWS, rhGH treatment should be considered and, if initiated, continued for as long as demonstrated benefits outweigh the risks. (Recommendation level A; level of evidence 1)

II. GH stimulation testing should not be required as part of the therapeutic decision-making process in infants and children with PWS. (Level of recommendation A; level of evidence 3)

III. Adults with PWS should have an evaluation of the GH/IGF axis prior to rhGH treatment. (Recommendation level A; level of evidence 3)

IV. Prior to initiation of rhGH therapy, patients with PWS should have a genetically confirmed diagnosis and expert multidisciplinary evaluation. (Recommendation level A; level of evidence 5)

V. Exclusion criteria for starting rhGH in patients with PWS include severe obesity, uncontrolled diabetes, untreated severe obstructive sleep apnea, active cancer and active psychosis. (Recommendation level A; level of evidence 4)

VI. Scoliosis should not be considered a contraindication to rhGH treatment in patients with PWS. (Recommendation level A; level of evidence 2)

VII. Infants and children with PWS should start with a daily dose of 0.5 mg/m²/day subcutaneously with subsequent adjustments toward 1.0 mg/m²/day every 3–6 months according to clinical response* and guided by maintenance of physiologic levels of IGF-I**. (Recommendation level A; level of evidence *1, **5)

VIII. Adults with PWS should receive a starting dose of 0.1–0.2 mg/day based on age, presence of edema, prior rhGH exposure and sensitivity, and concomitant oral estrogen use. Subsequent dosage titration should be based on clinical response, age, and sex appropriate IGF-I levels in the 0 to +2 SD range. (Recommendation level A; level of evidence 2)

IX. Selection of patients with PWS for rhGH therapy and dosing strategy should not depend on the genetic class of PWS (DEL15; UPD15; ID). (Recommendation level A; level of evidence 2)

X. IGF-I levels in patients with PWS on rhGH treatment should be maintained within the upper part of normal range (+1 to +2 SDS) for healthy, age-matched normal individuals. (Recommendation level B, level of evidence 3 (adults), 5 (children))

XI. Clinical outcome priorities should vary depending on the age, and on the presence of physical, mental, and social disability. (Recommendation level A; level of evidence 1)

XII. Monitoring of GH treatment in patients with PWS should address specific benefits and risks of treatment in this population and the potential impact of other hormonal deficiencies. (Recommendation level A; level of evidence 3)

XIII. Patients with PWS receiving GH must be followed carefully for potential adverse effects during GH treatment. (Recommendation level A; level of evidence 1)

XIV. Treatment with GH must be in the context of appropriate dietary, environmental, and lifestyle interventions necessary for care of all patients with PWS. (Recommendation level A; level of evidence 4)

XV. Cognitive impairment should not be a barrier to treatment with GH for patients with PWS. (Recommendation level A; level of evidence 4)

Recommendation levels: A, Evidence or general agreement that a given procedure of treatment is beneficial, useful and effective; B, Weight of evidence is in favor of usefulness or efficacy; C, Usefulness or efficacy is less well established by evidence or opinion; D, Evidence or general agreement that the procedure or treatment is not useful or effective and in some cases may be harmful. Levels of evidence: 1, Systematic review of randomized trials; 2, Randomized trial or observational study with dramatic effect; 3, Non-randomized controlled trial/follow-up study; 4, Case-series, case-control or historically controlled studies; 5, Mechanism-based reasoning

dance of diabetic complications such as retinopathy, demands attention prior to initiation of rhGH therapy in patients with PWS (104).

Children with PWS have a high incidence of both central apnea and obstructive apnea (75–77). Marked obesity or intercurrent respiratory tract infection (often underdiagnosed because of the absence of fever), can exacerbate obstructive apnea and may even lead to sudden death (78–82). Since rhGH therapy can theoretically lead to lymphoid tissue growth in children due to increased IGF-I effects (100) patients and parents must be fully informed about the potential association between rhGH therapy and unexpected death during the pretreatment consenting process, and polysomnography should be performed before starting therapy. rhGH therapy is contraindicated in children with breathing difficulties until ENT surgery and treatment of respiratory-compromising obesity has been achieved. Therapy should not be initiated during an acute respiratory infection, but it need not be interrupted during subsequent episodes of respiratory infection unless indicated because of onset of breathing difficulties.

Scoliosis in PWS is not a contraindication to rhGH treatment; its occurrence is common (up to 30%–80% depending on age), but neither its incidence nor its rate of progression are influenced by rhGH therapy (21).

The potential role of the GH-IGF axis in cancer incidence and/or progression has received a great deal of recent attention (83) despite the safety record, to date, of rhGH treatment. The recent SAGhE publications do not specifically address rhGH use in patients with PWS, and a true appreciation of dose-related risks of rhGH will require better and longer surveillance protocols, since all observational studies are subject to bias (84, 85), (86, 87)

The potential development of central adrenal failure, which may not be clinically relevant except during intercurrent illness and/or surgical intervention, was also discussed. Investigations have not uniformly documented a high incidence of central adrenal failure in PWS (88–90).
Table 2. Multi-disciplinary Evaluation of Pediatric and Adult Patients with PWS Before Starting rhGH Treatmenta

<table>
<thead>
<tr>
<th>Evaluation</th>
<th>Testing/Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Endocrine examination to document anthropomorphic status: weight, length/height, BMI (and if possible, waist circumference and skinfold thickness), pubertal status and presence of additional endocrine deficiencies</td>
<td>● Bone age determination in infants and children</td>
</tr>
<tr>
<td>● Bone age determination in infants and children</td>
<td>● Evaluation of hypothyroidism (TSH, free T4, free T3) and commencement of replacement if appropriate</td>
</tr>
<tr>
<td>● Evaluation of hypothyroidism (TSH, free T4, free T3) and commencement of replacement if appropriate</td>
<td>● Determination of IGF-I level and, if possible, GH response to provocative testing particularly in adult individuals</td>
</tr>
<tr>
<td>● Determination of IGF-I level and, if possible, GH response to provocative testing particularly in adult individuals</td>
<td>● Evaluation of metabolic status if age [mteq] 12 y and obesity: HbA1c, fasting insulin and glucose; consider oral glucose tolerance test (OGTT) if family history of diabetes, acanthosis nigricans or ethnic risk factors</td>
</tr>
<tr>
<td>● Evaluation of metabolic status if age [mteq] 12 y and obesity: HbA1c, fasting insulin and glucose; consider oral glucose tolerance test (OGTT) if family history of diabetes, acanthosis nigricans or ethnic risk factors</td>
<td>● Evaluation of cardiovascular risk profile as per guidelines for obese individuals: fasting total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol</td>
</tr>
<tr>
<td>● Evaluation of cardiovascular risk profile as per guidelines for obese individuals: fasting total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol</td>
<td>● Assess for hepatic steatosis as per guidelines for obese individuals: AST and ALT levels, abdominal ultrasound and biopsy where appropriate</td>
</tr>
<tr>
<td>● Assess for hepatic steatosis as per guidelines for obese individuals: AST and ALT levels, abdominal ultrasound and biopsy where appropriate</td>
<td>● Body composition evaluation if available (Dual-energy x-ray photon absorptiometry or bioelectrical impedance)</td>
</tr>
<tr>
<td>● Body composition evaluation if available (Dual-energy x-ray photon absorptiometry or bioelectrical impedance)</td>
<td>● Consider need for evaluation of adrenal function on an individual basis</td>
</tr>
<tr>
<td>● Consider need for evaluation of adrenal function on an individual basis</td>
<td>● DNA studies to confirm PWS</td>
</tr>
<tr>
<td>● DNA studies to confirm PWS</td>
<td>● Nutritional evaluation and advice including use of food diary, control of food environment, diet composition and caloric intake</td>
</tr>
<tr>
<td>● Nutritional evaluation and advice including use of food diary, control of food environment, diet composition and caloric intake</td>
<td>● Age-appropriate psychomotor testing</td>
</tr>
<tr>
<td>● Age-appropriate psychomotor testing</td>
<td>● Physiotherapy and Occupational Therapy referral</td>
</tr>
<tr>
<td>● Physiotherapy and Occupational Therapy referral</td>
<td>● Tonsillectomy and adenoidectomy where indicated</td>
</tr>
<tr>
<td>● Tonsillectomy and adenoidectomy where indicated</td>
<td>● Sleep oxymetry is mandatory prior to starting rhGH in all patients, preferably completed by polysomnographic evaluation</td>
</tr>
<tr>
<td>● Sleep oxymetry is mandatory prior to starting rhGH in all patients, preferably completed by polysomnographic evaluation</td>
<td>● Spine x-ray</td>
</tr>
<tr>
<td>● Spine x-ray</td>
<td>● Procurement of legal guardian consent and patient assent/consent according to age and cognitive status</td>
</tr>
</tbody>
</table>


bFor guideline references in obesity, see Lau et al., 2007(128), August et al., 2008(129) and Australian Government Department of Health and Ageing, 2009(130)
No consensus was reached concerning the need for adrenal axis testing prior to initiation of rhGH, but families and clinicians should remain vigilant and not hesitate to use stress doses of glucocorticoids as clinically indicated.

**Age at treatment initiation**

According to observational data, rhGH treatment is usually initiated at a mean age of 7 y, as reported by Takeda et al. (91) Increasingly, rhGH treatment is initiated earlier (10, 17, 72). Published data support benefits of rhGH treatment when started between 4–6 mo of age, (25, 34) but some experts are currently treating from as early as 3 mo. There was no consensus reached on age of rhGH start although all agreed to the benefits of treating before the onset of obesity, which often begins by 2 y of age.

**Dosing**

*a. Infants and children.* Evidence for efficacy in infants and children is based on trials using a dosage of 1.0 mg/m²/day achieved within approximately one month of starting treatment (50). Given that patients with PWS exhibit variable degrees of GHD and that salutary outcomes in RCTs were associated with doses of 1.0 mg/m²/day (higher than the dose of rhGH routinely used in congenital GHD) or higher, it is unknown whether similar outcomes could be replicated with rhGH doses that result in consistently normal IGF-I levels. IGF-I levels and IGF-I/IGFBP-3 ratios rise above 2SD in some patients on this dosage, theoretically presenting some risk (83). (26, 35, 38, 40, 51, 92, 93) The efficacy of doses lower than 1.0 mg/m²/day administered over a long period of time is unknown, however it has been suggested that the efficacy of lower doses of rhGH on body composition is decreased (50, 51). Infants and children with PWS should start with a daily dose of 0.5 mg/m²/day subcutaneously to minimize side effects, with subsequent adjustments toward 1.0 mg/m²/day; there was disagreement as to how rapidly this should occur (3–6 mo). If not using body surface area (BSA)-based calculations (recommended) it was felt prudent to base dose calculations on a nonobese weight for height in cases where overweight for height (BMI = 8fifth to 9fifth percentile) or obesity exists, particularly when starting rhGH therapy. There was a difference of opinion regarding the timing and frequency of IGF-I measurement before increasing dosage to 1.0 mg/m²/day in the pediatric population with PWS. Notably, patients with PWS appear to be highly sensitive to GH in terms of IGF-I generation (94, 94), and standard rhGH doses often results in IGF-I levels outside the normal range. Since lymphoid hyperplasia is related to the levels of IGF-I, (95) this might increase the risk of sleep apnea (81).

*b. Adults.* In adults with PWS rhGH doses tested in placebo-controlled and open-label trials have varied between 0.2 and 1.6 mg per day s.c., depending on the time period under rhGH treatment, weight and induced IGF-I levels. This dose range gives an acceptable side effect profile, (29, 59, 61–64, 96) as well as beneficial effects on body composition, psychological and behavioral problems, Quality of Life (QoL), and heart function and results in IGF-I levels within the range of age matched controls (59, 61, 63, 64, 96, 97). It was unanimously concluded that in adults with PWS, the optimal IGF-I level, i.e., the level where the rhGH treatment will have clear beneficial effects and at the same time the lowest, possible risk of adverse events, will be a value similar to 0 to +2 SDS (SD score, z-score) for age-matched controls.

**Monitoring and Potential Side Effects**

There was unanimous agreement that rhGH therapy should be supervised by pediatric or adult endocrinologists, ideally those experienced with the care of patients with PWS. Periodic monitoring of the safety and efficacy of the treatment is mandatory (Table 3).

In the past, rhGH therapy dose adjustments in children were routinely performed based on growth response and/or weight (or BSA) increases. Epidemiological data suggesting a potential link between IGF-I levels and some adverse events (83, 84, 98, 104) have motivated investigators to consider maintaining IGF-I levels within the physiologically normal range (0 to +2 SDS), an approach shown to be feasible in other conditions, such as rhGH treatment of children with idiopathic short stature or small for gestational age (SGA), where pharmacologic doses are used (99, 100). Workshop participants felt that for the pediatric age range, IGF-I levels in patients with PWS on rhGH treatment could therefore safely be maintained within the upper part of normal range (+1 to +2 SDS) for healthy, age-matched normal individuals. For the adult population, where discontinuation of treatment because of side effects is more frequently noted, an IGF-I of 0 to +2 SDS was suggested.

Table 4 summarizes the side effects that should be routinely monitored. While rhGH therapy has a favorable safety profile, the postulated association between unexpected death and rhGH treatment in children with PWS deserves special attention not only in the consenting process and pretreatment evaluation, but also during treatment (16, 97, 101, 102). During rhGH treatment, changes in breathing (particularly during sleep) should be promptly reported and evaluated by repeat oximetry and/or polysomnography within the first 3 to 6 mo of starting therapy. Longer-term rhGH therapy has been associated with improvement in respiratory function in chil-
Tolerability

Tolerability of rhGH by pediatric and adult patients with PWS is high, according to the workshop participants involved in RCTs. However, relatively few adults with PWS have been studied and insufficient data are available to judge whether adverse effects of rhGH, death due to other causes, or personal choice accounted for treatment cessation. For children with PWS treated with rhGH and for the first 6 months of treatment,

Table 3. Multi-disciplinary Evaluation of Pediatric Patientsa with PWS During rhGH Treatmentb

- Regular clinical assessment of height, weight, BMI, pubertal status, scoliosis, IGF-I, and side effects every 3–6 months
- Clinical assessment of body composition every 6–12 months by one or more of the following: waist circumference, skinfold thickness, DEXA (or other available technique for determining body fat and lean body mass).
- Yearly bone age determination, particularly during pubertal age range
- IGF-I determination every 6–12 months
- ENT assessment and sleeping oxymetry, or ideally, repeat polysomnography within the first 3–6 months
- If development or worsening of sleep-disordered breathing, snoring, or enlargement of tonsils and adenoids, ENT assessment, polysomnography, and IGF-I measurement are mandatory
- Fasting glucose, insulin and HbA1c; if obese and/or older than 12 y and/or acanthosis nigricans and/or family history of diabetes/ethnic risk factors, OGTT
- x-ray ± orthopedic assessment if concern or doubt about scoliosis progression
- Monitoring for hypothyroidism yearly or if symptoms
- Lipid profiles and liver function tests and/or liver ultrasound according to family history, age and weight status as per clinical guidelines for non-PWS patients, with referral to gastroenterologist if non-alcoholic fatty liver disease is suspected
- In cases of acute illness and suggestive symptomatology, obtain critical blood samples for measurement of cortisol and ACTH levels if possible, and assess adrenal glucocorticoid response to provocative testing where indicated
- Continued contact with nutritionist, physiotherapist/occupational therapist, speech therapist and psychologist (frequency to determine on a case-by-case basis)
- If marked deterioration in behavior with or without overt psychiatric symptoms, psychiatry assessment

aApplicable to adult patients with PWS with the exception of the radiologic evaluations (bone age monitoring, scoliosis monitoring).

Table 4. rhGH Potential Side Effects to Monitora

- Changes in physical features and body proportions (faces, hands, feet) or bone growth
- Peripheral edema
- Joint pain
- Sleep apnea/disordered breathing: snoring, respiratory pauses, excessive daytime sleepiness
- Pseudotumor cerebri/benign intracranial hypertension: headache, visual changes, nausea, dizziness
- Slipped capital femoral epiphysis: hip and/or knee pain, gait disturbance
- Insulin resistance: elevated fasting insulin
- Decreased T4 level (requires measurement of T3 to differentiate from true central hypothyroidism)
- Scoliosis (recent data suggest no causal relationship or exacerbation of progression)
- Stroke, intracranial bleeding

aShown are the reported side effects of GH treatment primarily in the pediatric population with, or without PWS. No published data are available concerning GH treatment in adults with PWS on joint pain, sleep apnea, epilepsy, intracranial hypertension, neoplasia and stroke/intracranial bleeding. Furthermore, none of the studies in PWS adults (longest follow-up 5 yr) have reported breast tenderness/enlargement, unexpected death.

Table 4. rhGH Potential Side Effects to Monitora

- Glucose intolerance/Type 2 Diabetes Mellitus particularly in obese patients or patients with positive family history
- Epilepsy (no known relationship but should be reported)
- De novo neoplasia (no known relationship but should be reported)
- Stroke, intracranial bleeding

aShown are the reported side effects of GH treatment primarily in the pediatric population with, or without PWS. No published data are available concerning GH treatment in adults with PWS on joint pain, sleep apnea, epilepsy, intracranial hypertension, neoplasia and stroke/intracranial bleeding. Furthermore, none of the studies in PWS adults (longest follow-up 5 yr) have reported breast tenderness/enlargement, unexpected death.

dren and adults, primarily due to improvements in respiratory muscle function as indicated by increases in peak expiratory flow (35, 50, 96). Data concerning rhGH effects on central respiratory drive are few and are difficult to interpret because of multiple confounders (103, 104). No data are available concerning rhGH treatment and sleep apnea in adults with PWS.

There was a consensus to include an evaluation of diabetes risk (determination of HbA1c, fasting glucose and insulin) in patients with PWS who are obese and/or who are older than 12 y or who have a positive family history of diabetes. Further studies are needed to refine these recommendations since insulin sensitivity and risk of metabolic syndrome in patients with PWS may vary depending upon degree of obesity, adipose tissue distribution, genetic background risk and use of antipsychotics (105–109).
lowed in phase 4 postmarketing surveys, the reported rate of side effects leading to treatment cessation in trials overall is low (110). The enthusiasm of parents of PWS children for rhGH therapy suggests that early cessation is lower than in other rhGH-treated patients with conditions like idiopathic short stature, Turner syndrome, and children who are born SGA.

**Clinical Outcome Variables and rhGH Non-Responsiveness**

In untreated children with PWS, auxological and body composition parameters tend to deteriorate over time, so if these continue to improve or to stabilize, treatment is usually continued until adult height or near-adult height is reached. However, if adult height attainment is used for the decision to stop rhGH therapy in adolescents with PWS, it is important to note that these patients often experience premature adrenarche and obesity, causing early closure of growth plates (111, 112).

For adults with PWS and GHD, treatment duration depends on primary clinical outcome (body composition, lipid metabolism, physical and psycho-social functioning) and occurrence of side effects (impairments of glucose metabolism, edema, heart disease) (62).

Controlled studies of continuous treatment through childhood, adolescence and the transitional period into adulthood are not available in PWS, yet there is a strong likelihood of continued benefit by inference from non-PWS organic GHD and observational studies in PWS.

It was agreed that psychomotor development should be the priority during infancy with body composition and growth becoming important during childhood and adolescence. The data on cognitive benefits of rhGH treatment in the pediatric setting are limited, but should positive effects be extended, this would likely become a top treatment priority (25, 26, 35, 113). The workshop participants concluded that metabolic outcome variables should become the important priority in adults with PWS, although muscular hypotonia, mental retardation and psycho-social dysfunction should continue to receive attention throughout the lifespan. The ultimate goal is an improvement in the patient’s well-being.

The definition of nonresponsiveness to rhGH is arbitrary, since there is a continuum in GH response. Many other anthropomorphic and biochemical parameters plateau after some years of treatment, but deteriorate subsequently if rhGH is stopped. Response criteria to rhGH will vary according to age, pubertal status, degree of growth retardation and duration of therapy. Workshop participants felt that a successful first year pediatric response to rhGH treatment includes a delta height SDS $> 0.3$, a first year height velocity increment of [mteq] $3 \text{ cm/year}$, or a height velocity SDS [mteq] $+1$. Workshop participants acknowledged the difficulty of having alternative, easily measurable, robust, validated, affordable clinical endpoints other than the initial growth response. When possible, attempts should be made to document favorable changes in psychomotor progress and development, body composition, strength and exercise tolerance and QoL for both patient and caregivers, and findings should be reviewed with all involved in the decision to continue treatment. Parameters that define the sustained success of therapy include adult height SDS, adult height SDS minus height SDS at start of rhGH, adult height minus predicted height at start of treatment, and adult height minus target height (based on sex-corrected mean parental height). Emerging data on genotype-phenotype correlations relevant to specific outcome measures targeted with rhGH therapy need to be repeated in additional cohorts before firm conclusions can be drawn (12, 101, 107).

**Use of Adjunct Therapies**

Nutritional management remains the mainstay of treatment of patients with PWS even during rhGH therapy. Regular contact with a dietitian knowledgeable about PWS is essential, initially to calculate desirable caloric increases during the failure to thrive period often observed in infants with PWS. Once the failure to thrive period is over, caloric requirements vary according to the nutritional phase of the patient and are typically approximately 80% those of children and adults without PWS (114). This entails surveillance of vitamin and trace element intake to insure that recommended daily allowances are achieved. When hyperphagia begins, or if weight percentiles are increasing (usually age 2–4 years), close supervision must be maintained to minimize food stealing. Locking the kitchen, refrigerator, and/or cupboards is often necessary. As members of the treating team, dieticians must regularly reinforce adherence to diet, environmental control and programmed physical activity (115–117).

In some children, particularly those who have inadequate dietary, environmental and/or lifestyle interventions, unacceptable weight gain may occur during therapy. All attempts should be made to sensitize the family as to the increased risks for obesity-related health concerns, and to explain that rhGH therapy should not be viewed as a weight loss solution.

Recent studies in adolescent and adult patients with PWS (90% untreated with rhGH) using cyclic, intensive exercise and nutritional restriction successfully lead to BMI reductions during the period of participation in the study (up to 6 years) (118). Long-term, rigorous exercise and strict nutritional control have not been tested against rhGH therapy at any age.
Multiple pharmacological approaches in PWS aimed at increasing energy expenditure and weight loss have not been successful in limited short-term trials, and are summarized in Table 5. The workshop participants agreed that surgical strategies to achieve weight loss have not been successful long term (initial weight loss followed by weight regain) and have been associated with frequent complications (intestinal malabsorption, infectious complications, gastric perforation and death), and should therefore be discouraged (119–124).

Table 5. Adjunct Therapies Attempted in PWS

<table>
<thead>
<tr>
<th>Pharmacological Strategies</th>
<th>Mechanism of Action</th>
<th>Limitations/Adverse Events</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sibutramine</td>
<td>- Noradrenergic reuptake inhibitor</td>
<td>- Modest weight loss efficacy</td>
<td>Padwal et al., 2007(131)</td>
</tr>
<tr>
<td></td>
<td>- Induces satiety without reducing metabolic rate</td>
<td>- Poor long-term compliance</td>
<td></td>
</tr>
<tr>
<td>Orlistat</td>
<td>- Inhibits pancreatic lipase</td>
<td>- Hypertension</td>
<td>Butler et al., 2006(115)</td>
</tr>
<tr>
<td>Bupropion and naltrexone</td>
<td>- Bupropion: Activates central melanocortin pathways in the arcuate nucleus (α-MSH and β-endorphin secretion); decreases hunger and increases energy expenditure</td>
<td>- Multiple side effects: Nausea, Dry mouth, Headache, Dizziness, Fatigue, Constipation, Insomnia, Possibility of alteration of mood and depression</td>
<td>Greenway et al., 2009(132)</td>
</tr>
<tr>
<td></td>
<td>- Naltrexone: Opioid inhibitor; blocks β-endorphin inhibition of α-MSH release (normal feedback disrupted); decreases hunger and increases energy expenditure</td>
<td>- Contraindicated in acute hepatitis or liver failure</td>
<td>Lee and Fujioka, 2009(133)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Padwal, 2009(134)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plodkowski et al., 2009(135)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zipf and Berntson, 1987(136)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Shapira et al., 2002(137)</td>
</tr>
</tbody>
</table>

(Continued)
Additional studies are required to ascertain the safety, efficacy, and tolerability of alternative pharmacological strategies. Table 5 continues:

<table>
<thead>
<tr>
<th>Pharmacological Strategies</th>
<th>Mechanism of Action</th>
<th>Limitations/Adverse Events</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatostatin analogs</td>
<td>- Modulatory effects on Na/H channels, GABAA receptors, and AMPA/kainate</td>
<td>- Multiple side effects: Fatigue, Difficulty concentrating, Paresthesia, Somnolence, Ataxia, Dizziness, Nephrolithiasis, Word-finding difficulty, Mild confusion, Sedation</td>
<td>- Smathers et al., 2003(138)</td>
</tr>
<tr>
<td></td>
<td>- Affects food-seeking behavior</td>
<td>- No benefits on weight or appetite in PWS</td>
<td>- De Waele et al., 2008(139)</td>
</tr>
<tr>
<td></td>
<td>- Inhibits ghrelin secretion</td>
<td>- Decreased insulin secretion</td>
<td>- Haqq et al., 2003(140)</td>
</tr>
<tr>
<td></td>
<td>- Limit the release of insulin</td>
<td>- Decreased insulin secretion</td>
<td>- Haqq et al., 2003(141)</td>
</tr>
<tr>
<td></td>
<td>- Decreases hyperphagia</td>
<td>- Impaired glucose tolerance</td>
<td>- Tan et al., 2004(142)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Risk of cholesterol gallstones</td>
<td>- Tzotzas et al., 2008(143)</td>
</tr>
<tr>
<td>Rimonobant</td>
<td>- Block endocannabinoid receptor CB1 in central and peripheral nervous systems and other key cells involved in body energy metabolism</td>
<td>- Efficacious weight loss</td>
<td>- Motaghedi et al., 2010(15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lack of compliance in adults with PWS due to high risk of psychiatric side effects (mood disorders, suicide)</td>
<td>-</td>
</tr>
<tr>
<td>Anorexigens gut hormones</td>
<td>- Incretin mimic: GLP-1 receptor agonist</td>
<td>- Lack of efficacy in subjects with PWS</td>
<td>- Purtell et al., 2011(144)</td>
</tr>
<tr>
<td>(e.g. exenatide)</td>
<td>- Increases insulin secretion</td>
<td></td>
<td>- Sze et al., 2011(145)</td>
</tr>
</tbody>
</table>
approaches to weight loss in PWS either alone or in combination with rhGH. Thus there is insufficient evidence to support use of currently available obesity management medications or bariatric surgery in conjunction with rhGH treatment for weight reduction in patients with PWS, and indeed, some may be contraindicated.

**Issues of Consent/Assent**

There are differences in national legal regulations dictating when a child reaches the age of consent (e.g., 18 in many countries). Informed assent of a child is required in circumstances where he or she is beginning to make more complex decisions; this requires that the child is capable of
some degree of understanding and appreciation of the clinical reasoning.

Even in cases of cognitive disability in an older child or adolescent with PWS, it is optimal that legal guardians remain surrogate decision-makers, but that physicians strive to obtain the patient’s assent for rhGH therapy, even if the patient has limited decision-making capacity. An adult patient with intellectual disability due to PWS may be capable of consenting to rhGH treatment if he/she is able to understand and appreciate his or her clinical circumstances. In circumstances in which an adult patient does not have the capacity to consent, a surrogate decision-maker is appropriate, guided by country- and state-specific guardianship laws (125). This assent/consent process fosters a doctor – patient relationship based on partnership, mutual trust, understanding and respect (32, 126, 127).

It is not known to what degree the cognitive impairment of the individual with PWS plays a role in physicians’ lack of recommendation for rhGH use, whether because of perceived difficulty in obtaining truly informed consent or because of physicians’ views on healthcare priorities. All participants felt that cognitive impairment should not be a barrier or a contraindication to discussion of rhGH treatment with the patient and caregivers.

Issues of Fair Access to rhGH.

According to several PWS support associations, access to the option of rhGH therapy is currently unevenly provided even in countries with drug approval for this indication. Members of the workshop felt that several factors currently contribute to differences in the availability of the option for rhGH therapy for patients with PWS: 1) A lack of parental awareness of treatment options and general impediments to healthcare, 2) Inadequate numbers of physician willing and qualified to prescribe rhGH and to regularly assess treatment response and potential adverse events, 3) Inability to pay for rhGH either through personal wealth or by participation in a healthcare system that supports rhGH treatment and monitoring costs for PWS.

In considering efficiency and best distribution of healthcare resources among desirable interventions for patients with PWS, a long list of important interventions must be considered, such as occupational and physical therapy (PT), speech and language therapy, social skills therapy, weight management therapy and behavioral therapy, ophthalmologic and orthopedic interventions, and neurologic, psychiatric and endocrine care (replacement therapies for sex hormones, GH, L-thyroxin, cortisol). Although rhGH therapy is costly, (91) compared to the cost of the provision of all of these services, the cost of rhGH may be relatively modest. However, a true understanding of the healthcare burden of treating individuals with PWS requires long term health outcome research studies.

Future Directions

At the end of the meeting, workshop participants were asked to individually rank, in order of importance, areas needing further research that had been discussed during breakout sessions. It is not surprising that continued surveillance of long-term effects of rhGH treatment was considered the top priority, particularly with regards to glucose metabolism and diabetes risk, as well as sleep and sleep-disordered breathing. The impact of rhGH treatment on quality of life (QOL), not only of patients but also of their families, was also ranked as an important aspect of treatment response that needs additional documentation. Most of the attendees who were not physicians saw an important place for future clinical trials combining rhGH with other therapeutic approaches, particularly those targeting hyperphagia and behavior. The top 10 areas that received the highest priority scores can be seen in Table 6.

Conclusion

It is hoped that this PWS Workshop Summary will give patients, caregivers and physicians a framework with which to optimize care. More importantly, it is hoped that it will help harmonize the healthcare access of the pediatric and adult populations with PWS, not just with regards to rhGH treatment but also with regards to the need for lifelong follow-up of these patients by multidisciplinary teams with experience in PWS. Finally, we stress the importance of the ethical framework in which healthcare specialists working with patients with PWS should practice, and which should emphasize principles of informed consent/assent, respect for persons and distributive justice.

Acknowledgments

The workshop participants would like to thank the Foundation for Prader-Willi Research and the EVIDEM Collaboration, in particular, Dr. Mireille Goetghhebuer (President of the nonprofit EVIDEM Collaboration), for her help in preparing the methodological approach to this CPG and, along with Patricia Campbell, for the design and support of the PWS GH Evidence Registry and Workshop Website. We would also like to thank Dominika Kozubska, CHU-Ste-Justine Research Center, for her expert administrative assistance of the workshop. We gratefully acknowledge the provision of rhGH safety data from the following com-
Table 6. Areas Regarding rhGH Use for PWS Requiring Prioritized Attention in Future Studies

<table>
<thead>
<tr>
<th>TOP 10 areas for further research</th>
</tr>
</thead>
<tbody>
<tr>
<td>i.  Effects of rhGH therapy in adults with PWS on quality of life</td>
</tr>
<tr>
<td>ii. Long-term post-treatment effect of rhGH on mortality and morbidity using registries</td>
</tr>
<tr>
<td>iii. The optimal timing and dosage of rhGH treatment initiation in early life</td>
</tr>
<tr>
<td>iv. The effect of rhGH interruption at completion of growth</td>
</tr>
<tr>
<td>v. Effects of rhGH on behavior and cognitive function across the age range</td>
</tr>
<tr>
<td>vi. Impact of rhGH treatment on activities of daily living and well-being as defined by WHO</td>
</tr>
<tr>
<td>vii. Influence of IGF-I titration on clinical effects</td>
</tr>
<tr>
<td>viii. Effect of rhGH on glucose metabolism/diabetes risk, mainly long term effect</td>
</tr>
<tr>
<td>ix. Effects of rhGH therapy on sleep and sleep-disordered breathing in PWS adults</td>
</tr>
<tr>
<td>x. RCT trials investigating combination approaches to treatment</td>
</tr>
<tr>
<td>x. Additional areas for future research</td>
</tr>
<tr>
<td>xi. Effects of GH/IGF-I on nasopharyngeal tissue and mainly if adenotonsillectomy changes the course or may avoid potential side effects of rhGH on sleep disorders and OSA</td>
</tr>
<tr>
<td>xii. Dose response relationships investigating efficacy of physiologic (rather than pharmacologic) dosing</td>
</tr>
<tr>
<td>xiii. Effects of rhGH treatment in children and adults on visceral adiposity and ectopic fat e.g. muscle, liver and pancreas</td>
</tr>
<tr>
<td>xiv. Effects of rhGH on timing of development or severity of hyperphagia</td>
</tr>
<tr>
<td>xv. Effect of rhGH on bone maturation and premature puberty</td>
</tr>
<tr>
<td>xvi. Effects on structural brain development</td>
</tr>
<tr>
<td>xvii. Scoliosis and slipped capital femoral epiphysis in children</td>
</tr>
<tr>
<td>xviii. Is there hypersensitivity to rhGH in PWS?</td>
</tr>
<tr>
<td>xix. Thyroid function before and after rhGH</td>
</tr>
<tr>
<td>xx. Effects on cardiac function</td>
</tr>
<tr>
<td>xxi. Effects of rhGH on lipid metabolism</td>
</tr>
<tr>
<td>xii. Effects of rhGH on water retention</td>
</tr>
<tr>
<td>xiii. Intracranial hypertension (difficult to assess in young children)</td>
</tr>
</tbody>
</table>

*aAll participants were asked to discuss areas for future investigation within breakout groups. All participants were then asked to order, by priority, using a secret ballot.

Companies: Genetech-Hoffman LaRoche, Lilly, Novo-Nordisk, Pfizer, and Serono.

Address all correspondence and requests for reprints to: Corresponding author, to whom reprint requests should be directed: Cheri Deal, Ph.D., M.D., F.R.C.P.C., Endocrine Service, CHU-Sainte-Justine/Université de Montréal, 3175 Côte Ste-Catherine, Montréal, Québec H3T 1C5, CANADA, Cheri.L.Deal@umontreal.ca.

*a Participants of the workshop: Ambler, Geoffrey R.: Institute of Endocrinology and Diabetes, The Sydney Children’s Hospitals Network (Westmead) and The University of Sydney, Australia, Battista, Renaldo: Department of Health Administration, University of Montreal, Canada, Beauloye, Veronique: Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, France, Berall, Glen: Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The Hospital for Sick Children, Canada, Biller, Beverley MK: Department of Medicine, MA General Hospital, USA, Butler, Merlin G: Departments of Psychiatry, Behavioral Sciences and Pediatrics, KS University Medical Center, USA, Cassidy, Suzanne B.: Division of Medical Genetics, Department of Pediatrics, University of California, USA, Chihara, Kazuo: Hyogo Prefectural Kagokawa Medical Center, Japan, Cohen, Pinchas: Department of Pediatric Endocrinology, Mattel Children’s Hospital at UCLA, USA, Craig, Maria: Institute of Endocrinology and Diabetes, Sydney Children’s Hospital Network (Westmead); University of New South Wales, University of Sydney, Australia, Farholt, Stense: Centre for Rare Diseases, Aarhus University Hospital Skejby, Denmark, Goetghbeuer, Mireille: LA-SER, Montreal Canada; Department of Health Administration, University of Montreal, Canada; EVIDEM Collaboration, Canada, Goldstone, Anthony P.: Metabolic and Molecular Imaging Group, MRC Clinical Sciences Centre, Imperial College London, and Imperial Centre for Endocrinology, Hammersmith Hospital, UK, Greggi, Tiziana: Spine and Surgical Division, Istituto Ortopedico Rizzoli, Italy, Grugni, Graziano: Pediatric Endocrinologist, Istituto Auxologico Italiano, Research Institute, Italy, Hokken-Koelega Anita C.: Erasmus University Medical Center/ Sophia Children’s Hospital Rotterdam, Johannsson, Guðmundur: Department of Endocrinology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Johnson, Keegan: Foundation for Prader-Willi Research, USA, Kemper, Alex: Department of Pediatrics, Duke University, USA, Kopchick, John J.: Edison Biotechnology Institute, OH University, USA, Malozowski, Saul: National Institutes of Health, USA, Miller, Jennifer: Pediatric Endocrinologist, University of Florida, USA, Mogul, Hariette R.: Division of Endocrinology, NY Medical College, USA, Muscatelli, Francoise : Mediterranean Institute of Neurobiology (INMED), INSERM U901, France, Nergardh, Ricard: Division of Pediatric Endocrinology, Astrid Lindgren Childrens Hospital, Karolinska Institute, Sweden, Nicholls, Robert D.: Division of Medical Genetics, Department of Pediatrics, Children’s Hospital of Pittsburgh, USA, Radovich, Sally: Pediatric Endocrinology, John Hopkins Children’s Center, USA, Rosenthal, M. Sara: Associate Professor, Program for Bioethics, Depts. of Internal Medicine and Pediatrics, University of Kentucky, USA, Sipilä, Ilkka : Pe-diatrie, Hospital for Children and Adolescents, University of Helsinki, Finland, Tarride, Jean-Eric: Associate professor (part Time), Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada, Tony, Michèle: Département d’administration de la santé, Université de Montréal, Canada, Vogels, Annick: Kinder-en jeugdpsychiater, Centrum Menselijke Erfelijkheid, Belgium, Waters, Michael J.: Institute for Mo-
lcellular Biosciences and School of Biomedical Sciences, University of Queensland, Australia

Disclosure Statement: DBA, RB, RDN, MGB, VB, SBC, KC, MC, JSC, AK, GG, MG, TG, JJK, JM, SM, RN, SR, MT, AV, and MJW have nothing to declare. GRA has previously consulted for Pfizer (March 2012 to June 2012) and received grant support from Pfizer (2011 and 2012) and Ipsen (2011 and 2012). GB has previously consulted for Nestle Nutrition, has served as an expert witness for various legal cases, has received lecture fees from Abbott Nutrition, is an inventor on Hong Kong patent 07111326.5, Europe patent 0575924.6, Australia patent 2005253661, USA patent 11/570,740, Singapore patent 200608776–1, Japan patent 2007–515753, China patent 20058002768.1, and USA patent 12/401,505, and consults for Abbott Nutrition. BMKB received grant support from Novo Nordisk (2011 and 2012), Pfizer (until Dec 2011), and Serono (2011), and consults for Novo Nordisk and Pfizer. PC has previously consulted for Ipsen (2011), Medivation (2011), Theratechnicals (2011), L-Nutra (2011), and Serono (2011), has equity interests in CohBar Inc., received grant support from Amergen, Genentech, Eli Lilly and Pfizer, is an inventor on USA Patent 02307K-182710, and consults for Novo Nordisk and Teva.CD has consulted and received lecture fees for Lilly, Serono, Sandoz, Novo Nordisk and Pfizer. SF has received lecture fees from Novo Nordisk. CH has received lecture fees from Pfizer, Novo Nordisk and Ipsen. APG has received a grant from Pfizer 2011–2012. ACHK received lecture fees from Novo Nordisk, Pfizer, and Ferring, has received unrestricted research grants from Pfizer Netherlands for the Dutch PWS Cohort study 2010–2012 and the Dutch SGA study 2010–2012, and an unrestricted research grant from Novo Nordisk for the Dutch IUGR and Follow-up studies 2010–2012. GJ has received lecture fees from Novo Nordisk, Pfizer, Eli Lilly, Otsuka, and Merck Serono, and consults for Viropharma, Otsuka and Astra Zeneca. KJ was previously employed by Etheca and Cryptologie (2000–2005) and consults for Foundation for Prader Willi Research.HRM has received grant support from Glaxo Smith Kline (2007–2012), Lilly (2003–2012) and consults for Pfizer. FM is an inventor on FRANCE patent EP10305545.5. SR has previously consulted for Genentech on a Grant advisory committee and has received grant support from NIH. IS has received lecture fees and consults for Oy Eli Lilly Finlad Ab, NovoNordisk Farma Oy, and Pfizer Oy. JET is employed by AstraZeneca Canada since May 28 2012. MT received lecture fees from Pfizer and Novo Nordisk and is on a Pfizer and Ipsen advisory board.

1National Cooperative Growth Study (Genentech), Genetics and Neurendocrinology of Growth International Study (Lilly), Kabi International Growth Study (Pfizer), GH Moniter (EMD Serono), Nordinet and ANSWER (Novo Nordisk).

This work was supported by This workshop was supported by grants from the Growth Hormone Research Society and from the Foundation for Prader-Willi Research. A grant-in-kind was provided by the EVIDEM Collaboration for support of the PWS Workshop Website and for subsequently maintaining the site open to the public. Michele Tony is supported by a doctoral scholarship from APOGÈE-Net/CanGèneTest Network.

References


105. Butler MG, Lee PDK, Whitman B. Management of Prader-Willi


140. Haqq AM, Farooqi IS, O’Rahilly S, Bradler DD, Rosenfeld RG, Pratt KL, LaFranchi SH, Purnell JQ. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(1):174–178.


152. Scheinman AO, Butler MG, Gourash L, Cuffari C, Kish W. Criti-